• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Relay Therapeutics, Inc. - Common Stock (NQ:RLAY)

    13.16 -1.79 (-11.97%)
    Streaming Delayed Price Updated: 1:21 PM EDT, Apr 28, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 3,861,374
    Open 14.79
    Bid (Size) 13.14 (700)
    Ask (Size) 13.16 (500)
    Prev. Close 14.95
    Today's Range 13.11 - 15.07
    52wk Range 2.670 - 17.32
    Shares Outstanding 121,613,181
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer
    From Relay Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026
    From Relay Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +60.9%
    +60.9%
    1 Month
    +40.7%
    +40.7%
    3 Month
    +73.4%
    +73.4%
    6 Month
    +78.3%
    +78.3%
    1 Year
    +303.7%
    +303.7%

    More News

    Read More
    News headline image
    Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. ↗
    Via The Motley Fool
    Relay Therapeutics Inc (NASDAQ:RLAY) Beats Q4 Revenue Estimates, Outlines Pivotal 2026 for Zovegalisib ↗
    Via Chartmill
    News headline image
    Nextech Trims Kymera at a Recent High — think Foolishly before acting. ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026
    From Relay Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones
    From Relay Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March
    From Relay Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer ↗
    Via The Motley Fool
    News headline image
    Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026
    From Relay Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Relay Therapeutics Insider Sells 21,000 Shares for $166,700 After 65% Run ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
    From Relay Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer
    From Relay Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate
    Via MarketMinute
    Topics ETFs Government Initial Public Offering
    News headline image
    Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
    From Equity Insider
    Via GlobeNewswire
    News headline image
    Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025
    From Relay Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Relay Therapeutics Director Sells $300,000 Worth of Shares. Here's Why Investors Shouldn't Panic. ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Beyond the Hype: AI’s Quiet Revolution in Niche Sectors Reshapes Industries from Medicine to Agriculture
    Via TokenRing AI
    Topics Artificial Intelligence Economy Emissions

    Frequently Asked Questions

    Is Relay Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Relay Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Relay Therapeutics, Inc. - Common Stock trade on?
    Relay Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Relay Therapeutics, Inc. - Common Stock?
    The ticker symbol for Relay Therapeutics, Inc. - Common Stock is RLAY on the Nasdaq Stock Market
    What is the current price of Relay Therapeutics, Inc. - Common Stock?
    The current price of Relay Therapeutics, Inc. - Common Stock is 13.16
    When was Relay Therapeutics, Inc. - Common Stock last traded?
    The last trade of Relay Therapeutics, Inc. - Common Stock was at 04/28/26 01:21 PM ET
    What is the market capitalization of Relay Therapeutics, Inc. - Common Stock?
    The market capitalization of Relay Therapeutics, Inc. - Common Stock is 1.60B
    How many shares of Relay Therapeutics, Inc. - Common Stock are outstanding?
    Relay Therapeutics, Inc. - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.